Felix Biotechnology

@felixbiotech

Passionate and focused on accelerating the development and deployment of novel biotherapeutics to manage microbes in human health and beyond.

Vrijeme pridruživanja: rujan 2019.

Tweetovi

Blokirali ste korisnika/cu @felixbiotech

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @felixbiotech

  1. proslijedio/la je Tweet
    30. sij
    Poništi
  2. 2. velj

    Many bacteria have stopped responding to drugs that used to kill them. Drugmakers have stopped responding to alarms about it. Can the system be fixed in time? does a great job framing the challenge.

    Poništi
  3. 30. sij

    The standard for-profit model in drug development is straightforward. But the string of big pharma exits and slew of biotech bankruptcies indicate that the model is sorely flawed when it comes to antibiotics. Excellent summary by .

    Poništi
  4. proslijedio/la je Tweet
    29. sij

    “The lingering fear of losing another antibiotic option are all constants in my life.” - . Our Q&A puts a face to the crisis and shows why the antibiotic pipeline needs to be more robust.

    Poništi
  5. proslijedio/la je Tweet
    27. sij

    The Troubling Rise of , Finding Solutions to Fix the Problem. Listen to it here: Subscribe and review our Podcast on iTunes:

    Poništi
  6. proslijedio/la je Tweet
    27. sij

    Concerns About Failures. Listen to it here: Subscribe and review our Podcast on iTunes:

    Poništi
  7. proslijedio/la je Tweet

    The World Health Organization warns of a growing health crisis as the pipeline for new antibiotics slows to a trickle and drug makers go out of business

    Poništi
  8. 19. sij

    "Private venture capital flowing into antibiotics dropped by about 70% between 2016 and 2019." Without the right pull incentives it is hard to fund innovation, the government can help, pass appropriate legislation.

    Poništi
  9. proslijedio/la je Tweet

    Biohaven was honored to speak at the Innovation Dinner last week in San Fran highlighting Yale spin-out companies growing biotech innovation in New Haven. Thx to , , , Kleo Pharmaceuticals, , Yiviva, , Stradefy Biosciences

    Poništi
  10. proslijedio/la je Tweet
    18. sij
    Poništi
  11. proslijedio/la je Tweet
    15. sij

    . Phage therapy not only treats antibiotic resistant infection, but restores susceptibility! Compassionate use IND data.

    Poništi
  12. proslijedio/la je Tweet
    14. sij

    Jennifer Doudna, UC Berkeley professor of molecular and cell biology and of chemistry, has won the 2020 Wolf Prize in Medicine, a prestigious international prize awarded in Israel for unique contributions to humanity.

    Poništi
  13. 14. sij
    Poništi
  14. proslijedio/la je Tweet
    13. sij

    CEO Rob McBride showing off 's amazing tech from and for treating deadly antimicrobial infections at !

    Poništi
  15. 9. sij

    Congrats to for kicking off their new phage clinical trial! We need new ways to manage bacterial infections, and help showing the role phage therapy can play in that future.

    Poništi
  16. 8. sij

    The environment plays a role in shaping how resistance evolves. Felix is currently using deep sequencing to better understand how resistance to phage therapy evolves in complex human samples.

    Poništi
  17. 8. sij

    We are excited that will be presenting Felix Biotechnology on Wed. Jan 15 at 3:10 pm at the Hilton SF, looking forward to meeting people interested in and .

    Poništi
  18. proslijedio/la je Tweet

    To spur investment in needed antibiotics we must create a natural market for them and pursue “pull” rather than just “push” incentives. The best idea is to allow Medicare to reimburse hospitals based on licenses for drugs meeting key public health criteria

    Poništi
  19. 31. pro 2019.

    "Phage-therapy is having a resurgence due to the rise of superbugs that are resistant to antibiotics." Great to see Phage-therapy recognized as one of the medical breakthroughs of 2019. &

    Poništi
  20. 26. pro 2019.

    "Bacteria are becoming increasingly resistant to antibiotics. At the same time, a lack of financial incentives is setting back efforts to discover new classes of antibiotics." Great work and

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·